Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease

• Published in: BMC neurology Vol. 11; no. 1; p. 100
• Main Authors: Kim, Han-Joon, Jeon, Beom S, Lee, Won Yong, Lee, Myoung Chong, Kim, Jae Woo, Kim, Jong-Min, Ahn, Tae-Beom, Cho, Jinwhan, Chung, Sun Ju, Grieger, Frank, Whitesides, John, Boroojerdi, Babak
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 10.08.2011; BioMed Central; BMC
• Subjects: Administration, Cutaneous; Administration, Oral; Agonists; Antiparkinson Agents - administration & dosage; Antiparkinson Agents - adverse effects; Antiparkinson Agents - pharmacokinetics; Dopamine; Dosage and administration; Drug Administration Schedule; Drug therapy; Drugs; Female; Humans; Indoles - administration & dosage; Indoles - adverse effects; Indoles - pharmacokinetics; Male; Middle Aged; Parkinson Disease - drug therapy; Parkinson's disease; Ropinirole

A recent trial involving predominantly Caucasian subjects with Parkinson Disease (PD) showed switching overnight from an oral dopaminergic agonist to the rotigotine patch was well tolerated without loss of efficacy. However, no such data have been generated for Korean patients. This open-label multi...